CBDY · Target Group Inc.
Substantial doubt about the company's ability to continue as a going concern.
“The unaudited accompanying condensed consolidated interim financial statements have been prepared assuming that the Company will continue as a going concern up to at least 12 months from the balance sheet date; however, the above condition raises substantial doubt about the Company's ability to do so.”View the 10-Q filed Aug 13, 2026
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Chart any reported metric, KPI or segment over time — the full statement history lives here
| Line Item | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $3.5M | $3.88M | $6.59M | $3.72M | $0 | $0 | $30K | $0 | $263 | $15.43K | $5918 | $0 | — | |
| $2.12M | $1.81M | $2.87M | $2.07M | $0 | — | $25K | $0 | — | — | — | — | — | |
| $1.37M | $2.07M | $3.73M | $1.66M | $0 | — | $5000 | $0 | — | — | — | — | — | |
| — | 53.28% | 56.51% | 44.49% | — | — | 16.67% | — | — | — | — | — | — | |
| — | — | — | — | — | — | — | $0 | $32.25K | $86.09K | $79.98K | $284.87K | $48.59K | |
| — | — | — | — | — | — | $136.46K | $534.67K | $34.44K | $1273 | $14.61K | $6800 | $0 | |
| — | — | — | — | — | — | — | — | $0 | $13.25K | $0 | — | — | |
| $911.6K | $898.4K | $916.21K | $811.65K | $885.23K | $971.52K | $292.94K | $111.08K | $0 | — | — | — | — | |
| $2.18M | $2.29M | $2.61M | $2.09M | $1.24M | $1.35M | $1.57M | $4.69M | $1.28M | $924.74K | $1.67M | $2.75M | $358.21K | |
| $1.11M | $1.04M | $1.15M | $1.41M | $1.12M | $985.63K | $514.03K | $85.55K | $81.85K | $104.37K | $65.01K | $1543 | $133 | |
| — | $34.06K | $30.82K | — | — | — | — | — | — | — | — | — | — | |
| -$1.02M | -$1.14M | -$956.21K | $107.61K | -$3.28M | $1.62M | -$5.51M | -$5.68M | -$619.57K | -$833.38K | — | — | — | |
| — | — | — | $24.15K | $354.74K | -$273K | -$248.69K | $0 | — | — | — | — | — | |
| -$1.82M | -$1.36M | $160.5K | -$323.67K | -$4.52M | $272.88K | -$7.07M | -$10.37M | -$1.9M | -$1.74M | -$2.34M | -$2.75M | -$358.34K | |
| — | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | $0 | |
| -$1.82M | -$1.36M | $160.5K | -$323.67K | -$4.52M | $272.88K | -$7.07M | -$10.37M | -$1.9M | -$1.74M | -$2.34M | -$2.75M | -$358.34K | |
| — | -35.03% | 2.43% | -8.7% | — | — | -23579.57% | — | -722563.12% | -11291.19% | -39619.26% | — | — | |
| — | -$1.36M | $160.5K | — | — | — | — | — | — | — | — | — | — | |
| -$1.62M | -$1.56M | $465.07K | -$413.13K | -$4.41M | $337.13K | -$7.35M | -$10.87M | -$1.96M | -$1.74M | — | — | — | |
| USD/shares | -$0.00 | -$0.00 | $0.00 | -$0.00 | -$0.01 | $0.00 | -$0.01 | — | — | — | — | — | — |
| USD/shares | -$0.00 | -$0.00 | $0.00 | -$0.00 | -$0.01 | $0.00 | -$0.01 | — | — | — | — | — | — |
| shares | — | 617.03M | 617.03M | 617.03M | 617.03M | 595.35M | 566.88M | 410.38M | 46.2M | 2.41M | 27.32K | 8.05M | 10.48M |
| shares | — | 617.03M | 727.23M | 617.03M | 617.03M | 595.35M | 566.88M | 410.38M | 46.2M | 2.41M | 27.32K | 8.05M | 10.48M |
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2014–FY2015: $2000 in buybacks.
Debt Profile
Annual debt figures are established from 10-K filings and updated by subsequent 10-Q and 8-K disclosures. Instrument balances are not summed into a company total unless the filing itself reports that total.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
Peer medians compare against the 19 similar-size Drug Manufacturers - Specialty & Generic companies (of 96 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Product & Service (USD)
| Component | FY2020 |
|---|---|
| Membership Fees | $30,000 |